The acetylcysteine market was valued at USD 537.2 Mn by 2019. As per the latest research citings presented by the World Health Organization (WHO), it is anticipated that chronic obstructive pulmonary disease will be the 3rd largest cause of death throughout the globe by 2030. Rising prevalence of acetaminophen overdose throughout the globe will further bolster the market growth.

Acetylcysteine is basically a derivative of the cysteine molecule with an acetyl group attached to its amino acid. N-acetyl cysteine is the prodrug of cysteine which is absorbed via the intestines and is vital in replenishing the glutathione reserves of the liver. It is enlisted in the World Health Organization (WHO) list of essential medicines.

The major segments related to the acetylcysteine market are: 

By Treatment (2017–2027; US$ Mn)

Acetaminophen Overdose

Chronic Pulmonary Obstructive Disease (COPD)

Dietary Supplement

By End Users (2017–2027; US$ Mn)

Hospital and Clinics

Ambulatory Surgical Centers

Others

Geography Segment (2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global acetylcysteine market
• The overall segmentation of the acetylcysteine market, by treatment, end-users, and geography is minutely studied. Acetaminophen overdose and hospital & clinics are dominating the treatment and end-users segments respectively
• Significant increase in the number of patients suffering from infectious diseases often resulting in acetaminophen overdose
• Technological advancement in the development of inhalation sprays of acetylcysteine for the treatment of chronic obstructive pulmonary disease worldwide

Report gist?

• The study of the global acetylcysteine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and end-users and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical industry actively engaged in the manufacturing and marketing of acetylcysteine for the treatment of acetaminophen overdose in patients frequently taking acetaminophen to mitigate fever in infectious diseases
• The report will benefit formulation scientist actively engaged in the drug delivery technology of acetylcysteine for the treatment of cystic fibrosis
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to acetylcysteine market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Acetaminophen overdose in presently representing the largest market share in the treatment segment for acetylcysteine market. The major factor responsible for its market growth is the constant rise in patients suffering from fever associated with infectious disease worldwide. Acetaminophen overdose is associated with non- compliance to doctor’s prescription and in few cases gross negligence with the drug posology pertaining to acetaminophen. Its primary objective is to maintain and replenish the glutathione reserves of the liver and promote the non-toxic metabolism of acetaminophen. Chronic obstructive pulmonary disease (COPD) is a collective term used for the disease of the lower respiratory tract such as chronic bronchitis and emphysema. The clinical manifestation associated with COPD is shortness in breath due to excess secretion of mucus. Acetylcysteine inhalation is beneficial reducing the adhesiveness and viscosity of the mucus and promotes its expulsion from the lower respiratory tract. 

Hospitals and clinics are leading the end-user segment for the acetylcysteine market. Patients suffering from chronic bronchitis and emphysema need to be immediately admitted to the intensive care unit to stabilize their condition. Intravenous or inhalation dose of acetylcysteine needs to be started immediately as the treatment regimen. Ambulatory surgical centers have gained prominence in the developed regions owing to its ability to treat acetaminophen overdose in patients residing in remote locations. 

North America currently dominating the geography segment for the acetylcysteine market. As per the latest research citings brought forward by the Center for Disease Control and Prevention (CDC) the death rate of chronic pulmonary obstructive disease in the United States is approximately 44.3 per 100,000 people each year. Furthermore, the presence of key players such as Fresenius Kabi USA, LLC, Arbor Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sandoz, Inc., etc further propel the market growth in the region. Europe is placed in the 2nd position in the regional segment on account of the favorable reimbursement scenario for acetylcysteine used for the treatment of acute liver failure in the region. Asia Pacific is anticipated to be the fastest-growing regional segment in the acetylcysteine market. Rising prevalence of acetaminophen overdose on account of noncompliance to physician’s prescription and flourishing generic drugs market together determine the acetylcysteine market growth in the region.